EP2928300A4 - Behandlung von autistischen erkrankungen mit glycyl-l-2-methylprolyl-l-glutaminsäure - Google Patents

Behandlung von autistischen erkrankungen mit glycyl-l-2-methylprolyl-l-glutaminsäure

Info

Publication number
EP2928300A4
EP2928300A4 EP13858943.7A EP13858943A EP2928300A4 EP 2928300 A4 EP2928300 A4 EP 2928300A4 EP 13858943 A EP13858943 A EP 13858943A EP 2928300 A4 EP2928300 A4 EP 2928300A4
Authority
EP
European Patent Office
Prior art keywords
methylprolyl
glycyl
treatment
glutamic acid
spectrum disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13858943.7A
Other languages
English (en)
French (fr)
Other versions
EP2928300A1 (de
Inventor
Lawrence Irwin Glass
Michael John Bickerdike
Michael Frederick Snape
Cogram Patricia Perez De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUREN PHARMACEUTICALS Ltd
Original Assignee
NEUREN PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUREN PHARMACEUTICALS Ltd filed Critical NEUREN PHARMACEUTICALS Ltd
Publication of EP2928300A1 publication Critical patent/EP2928300A1/de
Publication of EP2928300A4 publication Critical patent/EP2928300A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP13858943.7A 2012-11-28 2013-11-26 Behandlung von autistischen erkrankungen mit glycyl-l-2-methylprolyl-l-glutaminsäure Withdrawn EP2928300A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
PCT/US2013/072049 WO2014085480A1 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (2)

Publication Number Publication Date
EP2928300A1 EP2928300A1 (de) 2015-10-14
EP2928300A4 true EP2928300A4 (de) 2016-07-13

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13858943.7A Withdrawn EP2928300A4 (de) 2012-11-28 2013-11-26 Behandlung von autistischen erkrankungen mit glycyl-l-2-methylprolyl-l-glutaminsäure

Country Status (6)

Country Link
EP (1) EP2928300A4 (de)
JP (1) JP2016506380A (de)
AU (1) AU2013352294A1 (de)
BR (1) BR112015012506A2 (de)
CA (1) CA2929286A1 (de)
WO (1) WO2014085480A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180184964A1 (en) * 2014-06-30 2018-07-05 Cerora, Inc. System and signatures for a multi-modal physiological periodic biomarker assessment
PL3833358T3 (pl) * 2018-08-10 2024-03-04 New York University Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu
MX2021001596A (es) 2018-08-10 2021-06-08 Univ New York Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental.
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (en) * 2001-05-24 2002-11-28 Neuronz Limited Gpe analogs and peptidomimetics
US20110112033A1 (en) * 2001-05-24 2011-05-12 Peter David Gluckman Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid
WO2011146109A2 (en) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US8461148B2 (en) * 2004-09-20 2013-06-11 Icahn School Of Medicine At Mount Sinai Use of memantine (namenda) to treat autism, compulsivity and impulsivity
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
PL2083811T3 (pl) * 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
SI2667715T1 (sl) * 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (en) * 2001-05-24 2002-11-28 Neuronz Limited Gpe analogs and peptidomimetics
US20110112033A1 (en) * 2001-05-24 2011-05-12 Peter David Gluckman Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid
WO2011146109A2 (en) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADRIAN BIRD: "The methyl-CpG-binding protein MeCP2 and neurological disease", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 36, no. 4, 1 August 2008 (2008-08-01), GB, pages 575 - 583, XP055276490, ISSN: 0300-5127, DOI: 10.1042/BST0360575 *
See also references of WO2014085480A1 *
WENLIN LIAO ET AL: "MeCP2+/ mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 46, no. 1, 31 December 2011 (2011-12-31), pages 88 - 92, XP028467473, ISSN: 0969-9961, [retrieved on 20120109], DOI: 10.1016/J.NBD.2011.12.048 *

Also Published As

Publication number Publication date
BR112015012506A2 (pt) 2017-07-11
JP2016506380A (ja) 2016-03-03
CA2929286A1 (en) 2014-06-05
AU2013352294A1 (en) 2015-07-09
WO2014085480A1 (en) 2014-06-05
EP2928300A1 (de) 2015-10-14

Similar Documents

Publication Publication Date Title
EP2667715A4 (de) Behandlung von leiden aus dem autismusspektrum mit glycyl-l-2-methylprolyl-l-glutaminsäure
EP2766014A4 (de) Verfahren zur behandlung von patienten im kindesalter mit dexmedetomidin
EP2744890A4 (de) Verfahren zur behandlung von störungen des magendarmsystems
EP2872493A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
EP2911664A4 (de) Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
EP2846825A4 (de) Behandlung von entzündlichen erkrankungen bei nichtmenschlichen säugern
EP2877184A4 (de) Zusammensetzungen und behandlungsverfahren für augenerkrankungen und störungen
EP2828247A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
EP2819519A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
EP2812004A4 (de) Verbindungen zur behandlung von spinaler muskelatrophie
EP2701733A4 (de) Verbindungen zur behandlung neuropsychiatrischer störungen
EP2827856A4 (de) Verbindungen und zusammensetzungen zur behandlung von muskelkrankheiten
EP2773342A4 (de) Zusammensetzungen zur behandlung von virenerkrankungen
EP3270914C0 (de) Verbindungen und formen zur behandlung von weiblichen sexuellen störungen
EP2723902A4 (de) Behandlung und diagnose epigenetischer störungen und erkrankungen
EP2903643A4 (de) Behandlung von psychiatrischen erkrankungen
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
EP2906594A4 (de) Verfahren und zusammensetzungen zur behandlung von multipler sklerose und verwandten erkrankungen
EP2841080A4 (de) Zusammensetzung zur behandlung von stoffwechselstörungen
EP2753365A4 (de) Mittel und verfahren zur behandlung entzündlichen leiden und erkrankungen
EP2673363A4 (de) Behandlung von angiogenesebeschwerden
EP2670442A4 (de) Verfahren und zusammensetzungen zur erhöhung einer sialsäureproduktion und zur behandlung sialsäure-vermittelter erkrankungen
EP2847342A4 (de) Reinigung von bernsteinsäure
MA42985A (fr) Traitement de troubles liés à l'acide biliaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160609

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/46 20060101AFI20160603BHEP

Ipc: C07D 207/00 20060101ALI20160603BHEP

Ipc: A61K 31/41 20060101ALI20160603BHEP

Ipc: A61P 25/28 20060101ALI20160603BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170110